Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC

The development of EGF receptor (EGFR)-tyrosine kinase inhibitors has recently provided a new therapeutic option for patients with advanced EGFR-mutant NSCLC; however, the long-term efficacy of such therapies is generally limited by the development of resistance. Recognizing the mechanisms underlying resistance and developing therapies to overcome key resistance pathways is an area of intense, ongoing investigation. In this review, we will provide an overview of EGFR-mutated lung cancer, primary and acquired resistance to EGFR-tyrosine kinase inhibitors and emerging therapeutic strategies designed to circumvent resistance.